Dr. O'Neil Discusses the Development of Biomarkers for CRC

Bert O’Neil, MD
Published Online: Friday, Aug 11, 2017



Bert O’Neil, MD, the Joseph W. and Jackie J. Cusick Professor of Oncology, professor of medicine, and director of the Phase I and Gastrointestinal Oncology Programs at Indiana University, discusses the development of biomarkers for colorectal cancer (CRC).

It is too early to state whether a biomarker will matter for combinations for the treatment of patients with CRC, explains O’Neil. Phase III data are needed to further investigate that question, but trials can be difficult to get started.



Bert O’Neil, MD, the Joseph W. and Jackie J. Cusick Professor of Oncology, professor of medicine, and director of the Phase I and Gastrointestinal Oncology Programs at Indiana University, discusses the development of biomarkers for colorectal cancer (CRC).

It is too early to state whether a biomarker will matter for combinations for the treatment of patients with CRC, explains O’Neil. Phase III data are needed to further investigate that question, but trials can be difficult to get started.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 1st Annual European Congress on Immunotherapies in Cancer™Dec 13, 20171.5
Community Practice Connections™: The Emergence of CAR-T Cell Therapy for Hematologic Malignancies: Moving From Bench to BedsideDec 29, 20171.5
Publication Bottom Border
Border Publication
x